Literature DB >> 3559209

Blood clearance of Streptococcus pneumoniae by C-reactive protein.

J Horowitz, J E Volanakis, D E Briles.   

Abstract

C-reactive protein (CRP) has long been known to be an acute phase protein associated with infection and various forms of tissue damage. Recent studies have shown that human CRP can be used to passively protect mice from lethal infection with Streptococci pneumoniae. In this study we have undertaken a detailed examination of the ability of human CRP and rabbit CRP (CxRP) to mediate the blood clearance of pneumococci in mice. We have shown that the optimal activity of these acute-phase proteins requires a functioning complement system, and it can take place even in the xid mouse, which has virtually no naturally occurring anti-pneumococcal antibody in its serum. These studies provide additional evidence that CRP may play a protective role in pneumococcal infections, and it may help postpone the development of fatal levels of pneumococci in the blood, long enough for an effective anti-pneumococcal antibody response to be generated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3559209

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Research pointers: Association of common genetic variant with susceptibility to invasive pneumococcal disease.

Authors:  S Roy; A V S Hill; K Knox; D Griffiths; D Crook
Journal:  BMJ       Date:  2002-06-08

2.  Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide.

Authors:  Madathilparambil V Suresh; Sanjay K Singh; Donald A Ferguson; Alok Agrawal
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

Review 3.  Molecular genetics, structure, and function of C-reactive protein.

Authors:  J M Kilpatrick; J E Volanakis
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

4.  Epidemiology and long-term clinical and biologic risk factors for pneumonia in community-dwelling older Americans: analysis of three cohorts.

Authors:  Sachin Yende; Karina Alvarez; Laura Loehr; Aaron R Folsom; Anne B Newman; Lisa A Weissfeld; Richard G Wunderink; Stephen B Kritchevsky; Kenneth J Mukamal; Stephanie J London; Tamara B Harris; Doug C Bauer; Derek C Angus
Journal:  Chest       Date:  2013-09       Impact factor: 9.410

5.  Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice.

Authors:  A J Szalai; J L VanCott; J R McGhee; J E Volanakis; W H Benjamin
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

6.  Decoration of lipopolysaccharide with phosphorylcholine: a phase-variable characteristic of Haemophilus influenzae.

Authors:  J N Weiser; M Shchepetov; S T Chong
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

Review 7.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

8.  The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice.

Authors:  Jeremy S Brown; Tracy Hussell; Sarah M Gilliland; David W Holden; James C Paton; Michael R Ehrenstein; Mark J Walport; Marina Botto
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-11       Impact factor: 11.205

Review 9.  The protective function of human C-reactive protein in mouse models of Streptococcus pneumoniae infection.

Authors:  Alok Agrawal; Madathilparambil V Suresh; Sanjay K Singh; Donald A Ferguson
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-12       Impact factor: 2.895

10.  CRP gene variation and risk of community-acquired pneumonia.

Authors:  Kenneth J Mukamal; Jennifer K Pai; Ellen S O'Meara; Russell P Tracy; Bruce M Psaty; Lewis H Kuller; Anne B Newman; Sachin Yende; Gary C Curhan; David S Siscovick; Eric B Rimm
Journal:  Respirology       Date:  2009-11-23       Impact factor: 6.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.